Dong-A PharmTech Co., Ltd.
Quick facts
Phase 2 pipeline
- DA-8159 · Diabetes
DA-8159 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Related
- Sector hub: All tracked pharma companies